Procédé de préparation de nouvelles chloroquinoléines
1,158,868. 4 - [(21 - Alkoxycarbonyl) - phenylamino] - quinoline derivatives. ROUSSEL UCLAF. 16 Feb., 1968 [22 Feb., 1967], No. 7819/68. Heading C2C. Novel 4 - [(21 - alkoxycarbonyl) - phenylamino] - quinoline derivatives of the general formula wherein R is a methyl or phenyl radical and R 1 is a C...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Patent |
Sprache: | fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1,158,868. 4 - [(21 - Alkoxycarbonyl) - phenylamino] - quinoline derivatives. ROUSSEL UCLAF. 16 Feb., 1968 [22 Feb., 1967], No. 7819/68. Heading C2C. Novel 4 - [(21 - alkoxycarbonyl) - phenylamino] - quinoline derivatives of the general formula wherein R is a methyl or phenyl radical and R 1 is a C 1-8 alkyl radical, an α- or #-glyceryl group or a furfuryl or methoxycarbonylmethyl group, the chlorine atom in the quinoline ring system being in the 7- or 8-position, and physiologically acceptable acid addition salts thereof are prepared by condensation under acidic conditions of an alkyl anthranilate derivative of the general formula with a 4,7- or 4,8-dichloroquinoline derivative of the general formula followed optionally by conversion of the resulting acid addition salt to the corresponding free base or a physiologically acceptable salt thereof. Pharmaceutical compositions having antiinflammatory activity comprise, as active ingredient, at least one 4-[(21-alkoxycarbonyl)- phenylamino]-quinoline derivative of the first general formula above or physiologically acceptable acid addition salt thereof, in association with a pharmaceutical carrier or excipient, and may be administered orally, transcutaneously, rectally or topically. |
---|